Recognizing Autoimmune-Mediated Encephalitis in the Differential Diagnosis of Limbic Disorders

A.J. da Rocha; R.H. Nunes; A.C.M. Maia; L.L.F. do Amaral

doi:10.3174/ajnr.A4408

Abstract

SUMMARY: Limbic encephalitis is far more common than previously thought. It is not always associated with cancer, and it is potentially treatable. Autoantibodies against various neuronal cell antigens may arise independently or in association with cancer and cause autoimmune damage to the limbic system. Neuroimaging plays a key role in the management of patients with suspected limbic encephalitis by supporting diagnosis and excluding differential possibilities. This article describes the main types of autoimmune limbic encephalitis and its mimic disorders, and emphasizes their major imaging features.

ABBREVIATIONS:

AME: autoimmune-mediated encephalopathy
AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
CASPR2: contactin-associated protein-like 2
GAD65: 65-kD isoform of glutamic acid decarboxylase
GABA: gamma-aminobutyric acid
HSE: herpes virus encephalitis
LE: limbic encephalitis
LGI1: leucine-rich glioma inactivated 1
PLE: paraneoplastic limbic encephalitis
TL: temporal lobe
VGKC: voltage-gated potassium channel

Limbic encephalitis (LE) was initially described in 3 patients with malignancies (and in the absence of a better explanation) as a subacute encephalitis of later adult life that mainly affected the limbic areas.¹ More than half a century later, most forms of LE have been recognized as a potentially treatable nonparaneoplastic autoimmune encephalopathy with a broad spectrum of recognizable symptoms that include psychiatric or behavioral features, seizures, hallucinations, and cognitive abnormalities.^2,3

Current knowledge has improved our recognition of the neurologic presentation and outcomes of patients with LE. Early diagnosis is always desirable because a satisfactory response to immunotherapy can be achieved.³ On electroencephalography or MR imaging, most patients with LE present inflammatory features in the CSF associated with temporal lobe (TL) abnormalities and detectable antineuronal antibodies.^3,4 However, LE is not the first diagnosis in clinical practice because clinical and paraclinical markers are often unavailable. In addition, symptoms can precede the diagnosis of cancer, and T2/FLAIR hyperintensity in the medial aspect of the TL may mimic several other disorders.^{4⇓⇓⇓⇓⇓⇓⇓–12}

MR imaging plays a key role in the management of patients with suspected LE and is used as part of the LE diagnostic criteria to rule out differential diagnoses. Certain imaging and clinical peculiarities may narrow the list of possible diagnoses; however, a complete list of differential diagnoses remains beyond the scope of this article. Our current aim was to describe the most commonly reported MR features of LE and its mimic disorders.

Autoimmune Encephalopathies

Both paraneoplastic LE (PLE) and nonparaneoplastic LE present a similar clinical picture that includes CSF and MR imaging abnormalities. It is estimated that 60% to 70% of cases are PLE; however, a neurologic disorder can precede neoplasia by months or even years.^2,3

Autoimmune-mediated encephalopathy (AME) can be distinguished by its association with autoantibodies^3,13 and by certain recognizable features on MR imaging, which (besides LE) include cerebellar degeneration, striatal encephalitis, brain stem encephalitis, and leukoencephalopathy.^14⇓–16 A comprehensive search for an underlying malignancy is always considered when AME is suspected.³ The position of the causal antigens is correlated with the disease mechanism and with concurrent cancer.^2,3,13 In general, antibodies against intracellular antigens are associated with cytotoxic T-cell mechanisms; in these cases, neuronal damage seems to be irreversible, associations are found with underlying malignancies and poor prognosis, and structural abnormalities are not restricted to the limbic structures.¹⁰ Conversely, in restricted LE, neuronal cell-surface antigens are targeted, an associated malignancy is unusual, and its expected response to immunotherapy is superior.³

Paraneoplastic LE

The classic mechanism reported in PLE is a systemic neoplasia that expresses coincident antigens within the CNS, which results in the production of antibodies that target neoplastic tissue (onconeural antigens) as well as intracellular antigens.^2,13,14 The correct diagnosis of PLE is relevant because earlier recognition often allows the discovery and treatment of the underlying malignancy. Cancer control is a crucial step in the management of PLE, which is usually followed by the remission of the paraneoplastic syndrome.¹⁷

PLE Associated with Autoantibodies against Intracellular Antigens

Hu Antibodies.

The Hu antineuronal nuclear antibody is a type IIa antineuronal nuclear antibody type I, which can appear in any part of the nervous system. Approximately 75% of the patients have small cell lung carcinoma and often develop symptoms related to inflammation across widespread areas of the CNS or the peripheral nervous system.¹⁸ MR imaging reveals variable abnormalities according to clinical features, including T2/FLAIR hyperintensity in the mesial TL (Fig 1), cerebellar edema or atrophy, and brain stem abnormalities.⁴ Rarely, patients have epilepsia partialis continua, which results from restricted lesions in nonlimbic cortical areas.¹⁹ First-line immunotherapies often fail, and the prognosis of this condition is usually poor despite immunotherapy.²⁰

Fig 1.

A 62-year-old man with subacute cognitive impairment and seizures. A, An enlarged and hyperintense right hippocampus in a coronal FLAIR image (arrowhead). Additional right amygdala involvement was observed, but no abnormal enhancement was documented after intravenous gadolinium administration (not shown). B, Body CT after contrast administration shows a right hilar mass (arrow) with an enlarged lower paratracheal lymph node (asterisk). Endobronchial biopsy specimen revealed an small cell lung carcinoma, and the diagnosis was consistent with PLE.

Ma2 Antibodies.

Patients with Ma2 antineuronal nuclear antibody–related encephalitis often have accompanying symptoms of diencephalic inflammation (sleep disturbances, dysthermia, and endocrine abnormalities) and upper brain stem inflammation (eye movement abnormalities and hypokinetic syndrome). Approximately 75% of patients have abnormal MRI, usually with classic LE findings.²¹ The remaining patients have signal abnormalities that are either isolated or associated with the hypothalamus and thalamus or with the brain stem.²² Nodular parenchymal enhancement in the affected regions has been reported, which may mimic a brain tumor or an infection.^21,22 This AME occurs mostly in association with testicular germinal cell tumors in younger male individuals; but, in older individuals, there may be an underlying non–small cell lung carcinoma or breast cancer.²³ Improvement with immunotherapy is more likely than in other forms of LE that involve antibodies against intracellular antigens.²²

CV2/Collapsing Response Mediator Protein-5 Antibodies.

Bilateral striatal encephalitis with T2/FLAIR hyperintensity is a typical finding, which causes choreiform movement disorders and is highly suggestive of CV2/collapsing response mediator protein-5 antineuronal nuclear antibody–related encephalitis associated with underlying small cell lung carcinoma or malignant thymoma, among others disorders.^24,25 However, patients may also present with a range of imaging patterns that rarely include LE and typically do not include striatal restriction on DWI, which may help to distinguish this AME from prion diseases.²⁵

PLE Associated with Autoantibodies against Extracellular Antigens

N-Methyl-D-Aspartate Receptor Antibodies.

A specific immunoglobulin G antibody against the GluN1 subunit of the anti–N-methyl-D-aspartate receptor results in a highly characteristic and recognizable LE that is far more common than previously believed²⁶ and mostly affects young women and children.²⁷ Two major well-characterized stages are noticeable.²⁸ A viral-like prodrome followed by severe psychiatric features characterizes the earliest involvement of the cortical regions. In addition, patients may develop amnesia and seizures.²⁹ After a few days to a few weeks, subcortical areas are affected and a movement disorder appears (often dyskinesia of the mouth and face) followed by a decreased level of consciousness and dysautonomia, which requires intensive care support. A lymphocytic pleocytosis is observed in the CSF, and, less commonly, increased protein and/or oligoclonal bands are present.²⁷

The most common MR imaging abnormality is unilateral or bilateral LE^30,31; however, approximately 66% of patients have an unremarkable MR imaging. Cerebellitis, striatal abnormalities, and brain stem encephalitis have also been described.^30,31 Gadolinium enhancement is uncommon, and imaging follow-up could reveal complete recovery or focal atrophy (Fig 2).^27,30,31

Fig 2.

A previously healthy 44-year-old woman presented with subacute psychiatric disturbance with no fever or seizures. A, Bilateral and asymmetric hyperintensity was observed on an axial FLAIR image in the enlarged amygdalae and hippocampi (asterisks), predominantly on the left side. B, A faint ill-defined enhancement of the left hippocampus was documented on an axial T1 postcontrast image (arrowheads). Autoimmune encephalitis was considered, and the presence of anti–N-methyl-D-aspartate receptor autoantibodies was confirmed. C and D, Imaging follow-up revealed signal abnormalities and atrophy on FLAIR that involved the hippocampus, amygdala, parahippocampal gyrus, and left insula (arrowheads), compatible with severe sequelae.

The concurrence of tumors is reportedly age dependent. Whereas approximately 45% of adult woman had ovarian teratoma, only 9% of younger girls had this type of tumor. Identification and removal of the tumor were crucial because patients without tumor removal recovered less frequently and had an increased risk of relapse.²⁷ In patients older than 45 years, the outcome was reportedly favorable, whereas 23% of patients had underlying carcinomas instead of teratomas.³² Despite this ominous clinical presentation, approximately 50% of patients respond to first-line immunotherapies, often with full remission, whereas patients who do not respond to treatment or who experience relapse should be reassessed for the presence of an underlying contralateral or recurrent teratoma.³³

Gamma-Aminobutyric Acid Receptor Antibodies.

Anti–gamma-aminobutyric acid (GABA) B-receptor antibody-related encephalitis usually presents as LE. Most patients have early and frequent seizures associated with unilateral or bilateral T2/FLAIR hyperintensity in the mesial TL that are potentially reversible after treatment.³⁴

As is most commonly reported in older patients, approximately 50% of patients with GABA B-receptor AMEs have underlying small cell lung carcinoma or lung neuroendocrine tumors.³⁵ This AME usually precedes a cancer diagnosis but represents the second most common cause of LE related to small cell lung carcinoma.³⁶

An AME associated with anti–GABA A-receptor antibodies was recently described in children and adults who developed a rapidly progressive encephalopathy with refractory seizures, status epilepticus, and/or epilepsia partialis continua that was preceded by or associated with behavioral changes.³⁷ Unlike patients with other LEs in whom MR imaging is either normal or shows predominant involvement of the limbic system, these patients have multifocal and extensive T2/FLAIR brain abnormalities. In addition, they respond well to immunotherapy and rarely have an underlying tumor. When a tumor is present, it is usually a thymoma. Patients are often misdiagnosed with the 65-kD isoform of glutamic acid decarboxylase (GAD65) antibody-associated encephalitis or Hashimoto encephalitis due to the frequent co-occurrence of GAD65 and antithyroid antibodies.^16,37

Other PLEs with Autoantibodies against Extracellular Antigens.

In anti–α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) encephalitis, patients develop antibodies against the GluR1 and GluR2 subunits of the AMPAR, and present with symptoms and MR imaging features of unilateral or bilateral LE that rarely involve extrahippocampal limbic structures. In some cases, the manifestations are purely psychiatric. Most of these patients are women who are harboring a tumor in the lung, breast, or thymus.³⁸

Hodgkin lymphoma is the third most common cause of LE after small cell lung carcinoma and testicular germ cell tumors.⁴ This association has been called Ophelia syndrome, and it is characterized by generalized or partial complex seizures in 50% of the patients. It is also more commonly associated with short-term memory loss or amnesia, psychiatric changes, and even frank psychosis with visual or auditory hallucinations or paranoid ideation.^17,39

Intriguingly, AME is not typically associated with non-Hodgkin lymphoma.¹⁷ Although Hodgkin lymphoma rarely infiltrates the CNS, the onset of an LE in this setting should be attributable to either a concurrent infection or an AME (Fig 3). Successful treatment of the tumor results in complete neurologic recovery, probably due to an association with an antibody against the metabotropic glutamate receptor 5, which is highly expressed in the hippocampus and presumably promotes reversible neuronal dysfunction rather than neuronal death.^17,40

Fig 3.

A 22-year-old man with Hodgkin lymphoma presented with acute onset of short-term memory loss and mental confusion. A, An evident hyperintensity and subtle enlargement of the right hippocampus and amygdala were noticed on an axial FLAIR image (arrow). B, No parenchymal enhancement was observed (arrowhead). In addition to the fact that CNS involvement is not expected in Hodgkin lymphoma, a lack of enhancement is not the expected imaging pattern. After the patient did not respond to antiviral treatment, PLE was considered. The findings fulfilled the criteria for Ophelia syndrome, which consists in an interval of <4 years between the onset of neuropsychiatric disturbance and the diagnosis of the Hodgkin lymphoma, exclusion of other cancer-related complications, and evidence of hippocampal abnormalities on MR imaging.

Nonparaneoplastic LE

It is assumed that nonparaneoplastic LE is more common than classic PLE and affects a wider age range of patients, though predominantly young patients. Nonparaneoplastic LE is a result of antibodies against neuronal cell surface or synaptic receptors.²

Nonparaneoplastic LE Associated with Autoantibodies against Intracellular Antigens

GAD65 Antibodies.

Some patients with nonparaneoplastic LE have antibodies against the intracellular antigen GAD65. However, unlike other intracellular antibodies, anti-GAD65 is not typically related to underlying malignancies. Patients typically present with stiff man syndrome or cerebellar ataxia, but they also may present with severe TL epilepsy, with less pronounced cognitive-behavioral features and a poorer response to first-line epilepsy drugs.⁴¹

MR imaging frequently shows signal abnormalities and swelling predominantly in the amygdala and hippocampus, which may resolve or progress to mesial temporal sclerosis on follow-up imaging (Fig 4).⁴¹

Fig 4.

A 38-year-old woman presented with personality and behavioral changes associated with progressive drug-resistant epilepsy. Memory testing revealed an anterograde episodic memory disorder, and electroencephalography showed TL epileptiform discharges. A, A selective hyperintensity in the hippocampi that extended to the amygdalae bilaterally was noticed on an axial FLAIR image, predominantly on the left side (arrow). B, Imaging follow-up revealed bilateral hippocampal sclerosis, which is shown in a coronal FLAIR image (arrowheads). Whole-body PET/CT and pelvic sonography were unremarkable (not shown). Autoimmune encephalitis was suggested, and a high titer of GAD65 antibodies was confirmed.

Nonparaneoplastic LE Associated with Autoantibodies against Extracellular Antigens

Voltage-Gated Potassium Channel-Complex Antibodies.

Anti–leucine-rich glioma inactivated 1 (LGI1) and anti–contactin-associated protein-like 2 (CASPR2) antibodies have been described as voltage-gated potassium channel (VGKC) antibodies and the most common cause of nonparaneoplastic LE.¹⁶ Results of recent studies highlight the relevance of discriminating both LGI1 and CASPR2 from VGKC-complex antibodies. Although LGI1 and contactin-associated protein-like 2 antibodies are specifically associated with limited subsets of syndromes, VGKC-complex antibodies lack specificity and may be found in nonautoimmune diseases, including Creutzfeldt-Jakob disease.^42,43

LGI1 antibodies occur most often in young male patients (2:1) who develop a classic LE with peculiar features, such as hyponatremia (60%), rapid eye movement–sleep behavior disorders, and normal CSF. In a few patients, a characteristic clinical manifestation described as faciobrachial dystonic or tonic seizures is observed. Fewer than 10% of patients with LGI1 antibodies have an underlying neoplasm, which is usually a thymoma.^16,44

Approximately 78.6% of patients present with typical LE MR imaging findings (Fig 5). Restricted DWI is observed in approximately 50% of these patients, whereas up to 25% have associated mild, ill-defined contrast enhancement and extrahippocampal involvement, including striatal encephalitis.^11,45

Fig 5.

A healthy 46-year-old woman presented with an acute onset of psychiatric disturbance and hyponatremia. A, Bilateral hyperintensity and mild enlargement were noticed on an axial FLAIR image in both hippocampi and amygdalae. B, No abnormal restricted diffusion was observed on DWI. The final diagnosis was anti-VGKC encephalitis. Restricted diffusion may occur in approximately 50% of patients at this phase and is usually restricted to the limbic system. The presence of faciobrachial dystonic or tonic seizures, hyponatremia, and unremarkable CSF in the setting of LE should raise concern that anti-LGI1 encephalitis is present.

Antibodies against the VGKC-complex have been identified in a subgroup of patients with epilepsy that appears on imaging as mesial temporal sclerosis, which indicates that some patients with epilepsy who are poorly responsive to conventional antiepileptic drugs may have an immune-mediated etiology.^11,46 Recognition and appropriate treatment with immunotherapy are recommended to prevent structural damage due to severe encephalitis as well as cognitive dysfunction.^16,47

LGI1 antibodies are almost exclusively expressed in the CNS. They often result in LE or epilepsy but primarily result in nonparaneoplastic LE (Fig 5). Conversely, CASPR2 antibodies expressed in the peripheral nervous system are involved in Morvan disease or peripheral nerve hyperexcitability–neuromyotonia spectrum disorders and are typically associated with thymomas. Myasthenia gravis and LE can also be found in some patients.⁴⁸

Limbic Disorders That Mimic AME

Abnormal MR signal intensity that involves the TL has a broad differential diagnosis that includes a range of unrelated disorders that are rarely reported, for example, Whipple disease,⁴⁹ 4-aminopyridine toxicity,⁵⁰ and hypoglycemia.⁵¹ Neuroradiologists must recognize these disorders and their imaging features more often.

Infectious LE

Herpes Virus Encephalitis.

Herpes virus encephalitis (HSE) causes at least 20% of acute LE cases.⁵² Although human herpes virus 6 is associated with posttransplantation acute LE,¹⁰ the most common agent is herpes virus type 1, which has high mortality and morbidity rates.⁵²

The clinical and imaging findings of LE caused by either AME or HSE may overlap. Although almost 50% of patients with AME present with or develop fever during their disease course and have prodromal symptoms with abnormal CSF, these findings favor HSE. The absence of psychiatric symptoms and the sudden and rapid progression also support the early administration of antiviral therapy based on a presumed diagnosis of HSE.¹⁰ In addition, even though both HSE and LE involve the TL, basal ganglia involvement on MR imaging favors nonherpetic etiologies.¹²

It has been demonstrated that some types of viral encephalitis can trigger autoimmune LE,^53,54 particularly anti-N-methyl-D-aspartate receptor encephalitis.⁵⁵ This phenomenon occurs when prolonged or atypical neurologic symptoms recur after successful control of the viral infection. Some patients with negative viral results develop a syndrome described as relapsing post-HSE or choreoathetosis post-HSE. A few weeks after recovery from HSE, children present with abnormal movement and adults present with behavioral changes that are not associated with additional brain lesions on MR imaging or response to antiviral therapy.

Neurosyphilis.

The incidence of neurosyphilis, caused by a spirochete (Treponema pallidum), has once again begun to increase in the era of acquired immunodeficiency syndrome.⁵⁶ MR imaging shows a variety of usually nonspecific findings, including selective involvement of the TL that mimics HSE and LE.^10,56 In older subjects with a long latency period of infection or in patients who are immunocompromised, T2/FLAIR hyperintensities in the mesial TL areas that may or may not be associated with either atrophic or gadolinium-enhanced areas increase the likelihood that neurosyphilis is present rather than other etiologies (Fig 6).

Fig 6.

A 47-year-old man with HSE. A, Bilateral symmetric cortical swelling and hyperintensity on axial FLAIR were observed in the anteromedial TLs (arrows) and also affected the insular cortex and rectus gyri (arrowhead). B, Restricted diffusion was documented in the same areas on DWI (asterisks). Bilateral and usually asymmetric involvement of the limbic system sparing the basal ganglia in the setting of acute LE should raise concerns for HSE. The presence of hemorrhagic foci and gyriform enhancement are also of diagnostic value in more-advanced disease. C, A similar pattern with bilateral asymmetrical involvement of the anteromedial TLs (arrows) on coronal FLAIR was observed in addition to the extensive white matter changes (arrowheads) in a 59-year-old man with progressive dementia who was later diagnosed with neurosyphilis.

Neoplastic Limbic Disorders

Diffuse gliomas and gliomatosis cerebri may mimic the imaging features of LE. The hallmark feature on MR imaging is an infiltrative pattern with poorly demarcated boundaries that is usually not restricted to the limbic system.^8,14,57 Gliomatosis cerebri, as well as low-grade diffuse gliomas, may progress slowly, with seizures or even focal deficits. Moreover, high-grade tumors might present with atypical imaging features that rarely mimic LE but then progress invariably to a recognizable MR imaging pattern of necrotic lesions (Fig 7). In this setting, MR-perfusion and MR-spectroscopy techniques are useful to detect brain tumors and enable surgical planning.⁵⁸

Fig 7.

A previously healthy 67-year-old man presented with a transient isolated episode of partial complex seizures and dysphasia. A, A cortical abnormality that involved the lateral aspect of the left TL (asterisk) and a subtle hyperintensity on coronal T2 were noticed in the ipsilateral hippocampus. B, Restricted diffusion on DWI was visible in the same areas (arrowhead), and a diagnosis of postictal edema was considered. C, After 2 months and a worsening of the clinical manifestations, a necrotic mass in the left TL (arrow) was observed on a T1 postcontrast image. A diagnosis of glioblastoma was confirmed after surgery. High-grade gliomas can manifest early as ill-defined lesions that usually have restricted diffusion and involve the cortex with a lack of a mass effect. Follow-up imaging and advanced imaging techniques are crucial for making the diagnosis.

Vascular Limbic Disorders

Differentiation between primary vasculitis and LE may represent a real challenge under certain conditions of subacute presentation. Abnormal vessels on angiography and cytotoxic edema on DWI that usually extends throughout the compromised vascular territory and is not restricted to the limits of the limbic system are helpful to confirm imaging suspicions.⁹ Transient global amnesia also affects the hippocampal formation, but its clinical and imaging presentation is rather typical.⁵⁹

Seizure-Related Limbic Disorders

Hippocampal sclerosis associated with TL abnormalities is the multifactorial hallmark of mesial temporal sclerosis. This condition could be a consequence of prolonged unilateral febrile seizures or status epilepticus, which occurs mainly in children when the hippocampus is more vulnerable to convulsion-induced excitotoxic damage and involves the sectors of the hippocampus rich in kainate or N-methyl-D-aspartate receptors and, therefore, that lack protection against calcium overload.⁶⁰

Prolonged seizures or status epilepticus may appear as TL abnormalities on MR imaging, including cortical hyperintensities on DWI that mimic LE and are attributable to hippocampal postictal edema.^9,61 Imaging follow-up with typical clinical and electroencephalographic features may aid diagnosis. This condition is potentially reversible or can result in atrophy with mesial temporal sclerosis (Fig 8).⁶²

Fig 8.

A 15-month-old child presented with a prolonged generalized tonic-clonic seizure episode. A, Extensive hyperintensity on an axial FLAIR image that involves the cortex and the white matter of the right TL (asterisk) indicated postictal edema. B, Comparative FLAIR imaging results on follow-up after 6 months are consistent with right mesial temporal sclerosis (arrowhead) in this patient who developed chronic epilepsy.

Hippocampal sclerosis may also be related to a rare neurodegenerative condition called pure hippocampal sclerosis dementia. Despite its similarity to mesial temporal sclerosis on imaging, dementia is always observed in the absence of epilepsy and usually occurs in the elderly.⁶³

Febrile infection–related epilepsy syndrome, or acute encephalitis with refractory repetitive partial seizures, is considered a severe epileptic encephalopathy with multifocal refractory status epilepticus, which occurs mostly in young children but also in adult patients.⁶⁴ The initial phase is characterized by a simple febrile infection, followed by an acute phase with recurrent focal seizures that evolve rapidly into refractory status epilepticus, generally without fever and additional neurologic features. The diagnosis is made after an exhaustive negative search for an active CNS infection and autoimmune or metabolic disorders. Early MR imaging may be normal in approximately half of the cases; however, T2 abnormalities are detected in some patients, predominantly in the temporal regions but also in the insula and basal ganglia, which mimics LE.^64,65 In the chronic phase, MR imaging shows mesial temporal sclerosis in half of the patients, and bilateral hypometabolism of orbitofrontal and temporoparietal regions is often demonstrated on PET.⁶⁴ The etiology and mechanisms that underlie it are still unknown, and, even though an autoimmune mechanism could be considered and autoantibodies have previously been described in epilepsy, up to now there is no evidence to support that autoantibodies are the etiology of febrile infection-related epilepsy syndrome.^64,66

Other Autoimmune Disorders

Autoimmune systemic disorders are associated with LE.² Sjögren syndrome, lupus erythematosus, Beçhet disease, primary angiitis of the CNS, and antiphospholipid syndrome can occasionally cause clinical and/or radiologic abnormalities in the limbic system that are not antibody mediated but that are accompanied by histopathologic evidence of cellular inflammation.³

Hashimoto encephalopathy or steroid-responsive encephalopathy associated with autoimmune thyroiditis⁶⁷ manifests as a diffuse progressive AME characterized by dementia, psychiatric disturbances, and seizures; there also is a vasculitic type characterized by multiple strokelike episodes, seizures, and fluctuating consciousness.⁶⁸ This disorder is more common in women and is associated with autoimmune antithyroid antibodies. There is increasing evidence that these antibodies are not pathogenic but rather are markers of autoimmunity for other associated but currently unclassified antineuronal antibodies.⁶⁹ MR imaging may mimic patterns of LE (Fig 9),⁷⁰ but leukoencephalopathy with bilateral patchy or confluent supratentorial subcortical and periventricular white matter T2/FLAIR hyperintensities is the most common abnormality and is usually reversible after corticotherapy.⁶⁷

Fig 9.

A 45-year-old woman presented with strokelike episodes associated with fluctuating and progressive cognitive impairment. Severe atrophy and bilateral hyperintensity in the hippocampi (arrowheads) along with mild cortical atrophy and scattered white matter changes were observed on a coronal FLAIR image. Although the patient had euthyroid status, she presented with high titers of serum antithyroperoxidase (490 U/mL; reference value, <60 U/mL). After excluding other causes, the diagnosis of steroid-responsive encephalopathy associated with autoimmune thyroiditis was considered.

A rare cause of LE is relapsing polychondritis, in which clinicoradiologic involvement of the limbic system might be more common than was previously thought.^71,72 This condition is a disorder of unknown etiology that manifests as episodic and progressive inflammation of the cartilaginous structures of the body, as is suggested by the detection of autoantibodies against type II collagen restricted to the cartilage in the sera of 30%–50% of affected patients.⁷³ MR imaging findings are coincident with LE; however, peculiar cartilage involvement may help identify this entity.

Recommended Diagnostic Approach to Limbic Disorders

An algorithm that describes an approach to the diagnosis of limbic disorders by using clinical and neuroimaging features is presented in Fig 10.

Fig 10.

Proposed approach to the diagnosis of LE and its mimic disorders. SCLC indicates small cell lung carcinoma; SIADA, syndrome of inappropriate antidiuretic hormone; TPO, thyroperoxidase; NMDA, N-methyl-D-aspartate; STREAT, steroid-responsive encephalopathy associated with autoimmune thyroiditis; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor.

Conclusions

LE and the mimic disorders presented in this review have always existed. However, they have just begun to be clearly distinguished over the past decade. Their association with autoantibodies influences their prognosis and results in recognizable imaging patterns that vary according to the position of the causal antigens (intra- or extracellular) and the concurrence of cancer. Mimic disorders may represent a complication of an underlying malignancy or may occur independently. MR imaging is the best technique for recognizing limbic disorders and is useful for differentiating among them and for improving their investigation.

Indicates open access to non-subscribers at www.ajnr.org

REFERENCES

1.↵
2. Brierley JB,
3. Corsellis JA,
4. Hierons R, et al
. Subacute encephalitis of later adult life mainly affecting the limbic areas. Brain 1960;83:357–68 doi:10.1093/brain/83.3.357
FREE Full Text
2.↵
2. Vernino S,
3. Geschwind M,
4. Boeve B
. Autoimmune encephalopathies. Neurologist 2007;13:140–47 doi:10.1097/01.nrl.0000259483.70041.55 pmid:17495758
CrossRef PubMed
3.↵
2. Tüzun E,
3. Dalmau J
. Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist 2007;13:261–71 doi:10.1097/NRL.0b013e31813e34a5 pmid:17848866
CrossRef PubMed
4.↵
2. Gultekin SH,
3. Rosenfeld MR,
4. Voltz R, et al
. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000;123(pt 7):1481–94 doi:10.1093/brain/123.7.1481 pmid:10869059
Abstract/FREE Full Text
5.↵
2. Vieira Santos A,
3. Matias S,
4. Saraiva P, et al
. Differential diagnosis of mesiotemporal lesions: case report of neurosyphilis. Neuroradiology 2005;47:664–67 doi:10.1007/s00234-005-1414-4 pmid:16021441
CrossRef PubMed
6.↵
2. Kararizou E,
3. Markou I,
4. Zalonis I, et al
. Paraneoplastic limbic encephalitis presenting as acute viral encephalitis. J Neurooncol 2005;75:229–32 doi:10.1007/s11060-005-3671-9 pmid:16283448
CrossRef PubMed
7.↵
2. Tyler KL
. Emerging viral infections of the central nervous system: part 1. Arch Neurol 2009;66:939–48 doi:10.1001/archneurol.2009.153 pmid:19667214
CrossRef PubMed
8.↵
2. Nagata R,
3. Ikeda K,
4. Nakamura Y, et al
. A case of gliomatosis cerebri mimicking limbic encephalitis: malignant transformation to glioblastoma. Int Med 2010;49:1307–10 doi:10.2169/internalmedicine.49.3278 pmid:20606365
CrossRef PubMed
9.↵
2. Förster A,
3. Griebe M,
4. Gass A, et al
. Diffusion-weighted imaging for the differential diagnosis of disorders affecting the hippocampus. Cerebrovasc Dis 2012;33:104–15 doi:10.1159/000332036 pmid:22179485
CrossRef PubMed
10.↵
2. Armangue T,
3. Leypoldt F,
4. Dalmau J
. Autoimmune encephalitis as differential diagnosis of infectious encephalitis. Curr Opin Neurol 2014;27:361–68 doi:10.1097/WCO.0000000000000087 pmid:24792345
CrossRef PubMed
11.↵
2. Kotsenas AL,
3. Watson RE,
4. Pittock SJ, et al
. MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis. AJNR Am J Neuroradiol 2014;35:84–89 doi:10.3174/ajnr.A3633 pmid:23868165
Abstract/FREE Full Text
12.↵
2. Oyanguren B,
3. Sánchez V,
4. González FJ, et al
. Limbic encephalitis: a clinical-radiological comparison between herpetic and autoimmune etiologies. Eur J Neurol 2013;20:1566–70 doi:10.1111/ene.12249 pmid:23941332
CrossRef PubMed
13.↵
2. Dalmau J,
3. Bataller L
. Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders. Hematol Oncol Clin North Am 2006;20:1319–35 doi:10.1016/j.hoc.2006.09.011 pmid:17113466
CrossRef PubMed
14.↵
2. Demaerel P,
3. Van Dessel W,
4. Van Paesschen W, et al
. Autoimmune-mediated encephalitis. Neuroradiology 2011;53:837–51 doi:10.1007/s00234-010-0832-0 pmid:21271243
CrossRef PubMed
15.↵
2. Darnell RB,
3. Posner JB
. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003;349:1543–54 doi:10.1056/NEJMra023009 pmid:14561798
CrossRef PubMed
16.↵
2. Dalmau J,
3. Rosenfeld MR
. Autoimmune encephalitis update. Neuro Oncol 2014;16:771–78 doi:10.1093/neuonc/nou030 pmid:24637228
Abstract/FREE Full Text
17.↵
2. Graus F,
3. Ariño H,
4. Dalmau J
. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood 2014;123:3230–38 doi:10.1182/blood-2014-03-537506 pmid:24705493
Abstract/FREE Full Text
18.↵
2. Graus F,
3. Keime-Guibert F,
4. Reñe R, et al
. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124(pt 6):1138–48 doi:10.1093/brain/124.6.1138 pmid:11353730
Abstract/FREE Full Text
19.↵
2. Shavit YB,
3. Graus F,
4. Probst A, et al
. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol 1999;45:255–58 doi:10.1002/1531-8249(199902)45:23.0.CO;2-N pmid:9989630
CrossRef PubMed
20.↵
2. Keime-Guibert F,
3. Graus F,
4. Fleury A, et al
. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000;68:479–82 doi:10.1136/jnnp.68.4.479 pmid:10727484
Abstract/FREE Full Text
21.↵
2. Rosenfeld MR,
3. Eichen JG,
4. Wade DF, et al
. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001;50:339–48 doi:10.1002/ana.1288 pmid:11558790
CrossRef PubMed
22.↵
2. Dalmau J,
3. Graus F,
4. Villarejo A, et al
. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004;127(pt 8):1831–44 doi:10.1093/brain/awh203 pmid:15215214
Abstract/FREE Full Text
23.↵
2. Dalmau J,
3. Gultekin SH,
4. Voltz R, et al
. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999;122(pt 1):27–39 doi:10.1093/brain/122.1.27 pmid:10050892
Abstract/FREE Full Text
24.↵
2. Honnorat J,
3. Cartalat-Carel S,
4. Ricard D, et al
. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009;80:412–16 doi:10.1136/jnnp.2007.138016 pmid:18931014
Abstract/FREE Full Text
25.↵
2. Vernino S,
3. Tuite P,
4. Adler CH, et al
. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002;51:625–30 doi:10.1002/ana.10178 pmid:12112110
CrossRef PubMed
26.↵
2. Gable MS,
3. Sheriff H,
4. Dalmau J, et al
. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012;54:899–904 doi:10.1093/cid/cir1038 pmid:22281844
Abstract/FREE Full Text
27.↵
2. Titulaer MJ,
3. McCracken L,
4. Gabilondo I, et al
. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157–65 doi:10.1016/S1474-4422(12)70310-1 pmid:23290630
CrossRef PubMed
28.↵
2. Irani SR,
3. Bera K,
4. Waters P, et al
. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133(pt 6):1655–67 doi:10.1093/brain/awq113 pmid:20511282
Abstract/FREE Full Text
29.↵
2. Kayser MS,
3. Titulaer MJ,
4. Gresa-Arribas N, et al
. Frequency and characteristics of isolated psychiatric episodes in anti–N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 2013;70:1133–39 doi:10.1001/jamaneurol.2013.3216 pmid:23877059
CrossRef PubMed
30.↵
2. Dalmau J,
3. Gleichman AJ,
4. Hughes EG, et al
. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–98 doi:10.1016/S1474-4422(08)70224-2 pmid:18851928
CrossRef PubMed
31.↵
2. Dalmau J,
3. Tüzün E,
4. Wu HY, et al
. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36 doi:10.1002/ana.21050 pmid:17262855
CrossRef PubMed
32.↵
2. Titulaer MJ,
3. McCracken L,
4. Gabilondo I, et al
. Late-onset anti-NMDA receptor encephalitis. Neurology 2013;81:1058–63 doi:10.1212/WNL.0b013e3182a4a49c pmid:23946310
Abstract/FREE Full Text
33.↵
2. Johnson N,
3. Henry C,
4. Fessler AJ, et al
. Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology 2010;75:1480–82 doi:10.1212/WNL.0b013e3181f8831a pmid:20826712
FREE Full Text
34.↵
2. Lancaster E,
3. Lai M,
4. Peng X, et al
. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010;9:67–76 doi:10.1016/S1474-4422(09)70324-2 pmid:19962348
CrossRef PubMed
35.↵
2. Höftberger R,
3. Titulaer MJ,
4. Sabater L, et al
. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013;81:1500–06 doi:10.1212/WNL.0b013e3182a9585f pmid:24068784
Abstract/FREE Full Text
36.↵
2. Boronat A,
3. Sabater L,
4. Saiz A, et al
. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011;76:795–800 doi:10.1212/WNL.0b013e31820e7b8d pmid:21357831
Abstract/FREE Full Text
37.↵
2. Petit-Pedrol M,
3. Armangue T,
4. Peng X, et al
. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014;13:276–86 doi:10.1016/S1474-4422(13)70299-0 pmid:24462240
CrossRef PubMed
38.↵
2. Graus F,
3. Boronat A,
4. Xifró X, et al
. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010;74:857–59 doi:10.1212/WNL.0b013e3181d3e404 pmid:20211911
FREE Full Text
39.↵
2. Carr I
. The Ophelia syndrome: memory loss in Hodgkin's disease. Lancet 1982;1:844–45 pmid:6122069
CrossRef PubMed
40.↵
2. Mat A,
3. Adler H,
4. Merwick A, et al
. Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF. Neurology 2013;80:1349–50 doi:10.1212/WNL.0b013e31828ab325 pmid:23486886
Abstract/FREE Full Text
41.↵
2. Malter MP,
3. Helmstaedter C,
4. Urbach H, et al
. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010;67:470–78 doi:10.1002/ana.21917 pmid:20437582
CrossRef PubMed
42.↵
2. Grau-Rivera O,
3. Sánchez-Valle R,
4. Saiz A, et al
. Determination of neuronal antibodies in suspected and definite Creutzfeldt-Jakob disease. JAMA Neurol 2014;71:74–78 doi:10.1001/jamaneurol.2013.4857 pmid:24248099
CrossRef PubMed
43.↵
2. Paterson RW,
3. Zandi MS,
4. Armstrong R, et al
. Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry 2014;85:625–30 doi:10.1136/jnnp-2013-305218 pmid:23757422
Abstract/FREE Full Text
44.↵
2. Irani SR,
3. Michell AW,
4. Lang B, et al
. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69:892–900 doi:10.1002/ana.22307 pmid:21416487
CrossRef PubMed
45.↵
2. Hiraga A,
3. Kuwabara S,
4. Hayakawa S, et al
. Voltage-gated potassium channel antibody-associated encephalitis with basal ganglia lesions. Neurology 2006;66:1780–81 doi:10.1212/01.wnl.0000218157.53333.79 pmid:16769968
FREE Full Text
46.↵
2. Majoie HJ,
3. de Baets M,
4. Renier W, et al
. Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res 2006;71:135–41 doi:10.1016/j.eplepsyres.2006.06.003 pmid:16870397
CrossRef PubMed
47.↵
2. Vincent A,
3. Buckley C,
4. Schott JM, et al
. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127(pt 3):701–12 doi:10.1093/brain/awh077 pmid:14960497
Abstract/FREE Full Text
48.↵
2. Lancaster E,
3. Huijbers MG,
4. Bar V, et al
. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011;69:303–11 doi:10.1002/ana.22297 pmid:21387375
CrossRef PubMed
49.↵
2. Blanc F,
3. Ben Abdelghani K,
4. Schramm F, et al
. Whipple limbic encephalitis. Arch Neurol 2011;68:1471–73 doi:10.1001/archneurol.2011.532 pmid:22084133
CrossRef PubMed
50.↵
2. Badruddin A,
3. Menon RS,
4. Reder AT
. 4-Aminopyridine toxicity mimics autoimmune-mediated limbic encephalitis. Neurology 2009;72:1100–01 doi:10.1212/01.wnl.0000345063.17185.13 pmid:19307545
FREE Full Text
51.↵
2. Boeve BF,
3. Bell DG,
4. Noseworthy JH
. Bilateral temporal lobe MRI changes in uncomplicated hypoglycemic coma. Can J Neurol Sci 1995;22:56–8 pmid:7750077
PubMed
52.↵
2. Baringer JR
. Herpes simplex infections of the nervous system. Neurol Clin 2008;26:657–74, viii doi:10.1016/j.ncl.2008.03.005 pmid:18657720
CrossRef PubMed
53.↵
2. Armangue T,
3. Leypoldt F,
4. Málaga I, et al
. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014;75:317–23 doi:10.1002/ana.24083 pmid:24318406
CrossRef PubMed
54.↵
2. Schäbitz WR,
3. Rogalewski A,
4. Hagemeister C, et al
. VZV brainstem encephalitis triggers NMDA receptor immunoreaction. Neurology 2014;83:2309–11 doi:10.1212/WNL.0000000000001072 pmid:25378669
Abstract/FREE Full Text
55.↵
2. Höftberger R,
3. Armangue T,
4. Leypoldt F, et al
. Clinical neuropathology practice guide 4–2013: post-herpes simplex encephalitis: N-methyl-Daspartate receptor antibodies are part of the problem. Clin Neuropathol 2013;32:251–54 doi:10.5414/NP300666 pmid:23806220
CrossRef PubMed
56.↵
2. Karsan N,
3. Barker R,
4. O'Dwyer JP
. Clinical reasoning: the “great imitator.” Neurology 2014;83:e188–96 doi:10.1212/WNL.0000000000001033 pmid:25422404
Abstract/FREE Full Text
57.↵
2. Vates GE,
3. Chang S,
4. Lamborn KR, et al
. Gliomatosis cerebri: a review of 22 cases. Neurosurgery 2003;53:261–71, discussion 271 doi:10.1227/01.NEU.0000073527.20655.E6 pmid:12925240
CrossRef PubMed
58.↵
2. Maia AC Jr.,
3. Malheiros SM,
4. da Rocha AJ, et al
. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion-weighted magnetic resonance imaging. J Neurosurg 2004;101:970–76 doi:10.3171/jns.2004.101.6.0970 pmid:15597757
CrossRef PubMed
59.↵
2. Sedlaczek O,
3. Hirsch JG,
4. Grips E, et al
. Detection of delayed focal MR changes in the lateral hippocampus in transient global amnesia. Neurology 2004;62:2165–70 doi:10.1212/01.WNL.0000130504.88404.C9 pmid:15210876
Abstract/FREE Full Text
60.↵
2. Cendes F
. Febrile seizures and mesial temporal sclerosis. Curr Opin Neurol 2004;17:161–64 doi:10.1097/00019052-200404000-00013 pmid:15021243
CrossRef PubMed
61.↵
2. Kim JA,
3. Chung JI,
4. Yoon PH, et al
. Transient MR signal changes in patients with generalized tonicoclonic seizure or status epilepticus: periictal diffusion-weighted imaging. AJNR Am J Neuroradiol 2001;22:1149–60 pmid:11415912
Abstract/FREE Full Text
62.↵
2. Cox JE,
3. Mathews VP,
4. Santos CC, et al
. Seizure-induced transient hippocampal abnormalities on MR: correlation with positron emission tomography and electroencephalography. AJNR Am J Neuroradiol 1995;16:1736–38 pmid:7502985
Abstract
63.↵
2. Hatanpaa KJ,
3. Blass DM,
4. Pletnikova O, et al
. Most cases of dementia with hippocampal sclerosis may represent frontotemporal dementia. Neurology 2004;63:538–42 doi:10.1212/01.WNL.0000129543.46734.C0 pmid:15304590
Abstract/FREE Full Text
64.↵
2. Caraballo RH,
3. Reyes G,
4. Avaria MF, et al
. Febrile infection-related epilepsy syndrome: a study of 12 patients. Seizure 2013;22:553–59 doi:10.1016/j.seizure.2013.04.005 pmid:23643626
CrossRef PubMed
65.↵
2. van Baalen A,
3. Häusler M,
4. Boor R, et al
. Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood. Epilepsia 2010;51:1323–28 doi:10.1111/j.1528-1167.2010.02535.x pmid:20345937
CrossRef PubMed
66.↵
2. Venkatesan A,
3. Benavides DR
. Autoimmune encephalitis and its relation to infection. Curr Neurol Neurosci Rep 2015;15:3 doi:10.1007/s11910-015-0529 pmid:25637289
CrossRef PubMed
67.↵
2. Castillo P,
3. Woodruff B,
4. Caselli R, et al
. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006;63:197–202 doi:10.1001/archneur.63.2.197 pmid:16476807
CrossRef PubMed
68.↵
2. Hollowell JG,
3. Staehling NW,
4. Flanders WD, et al
. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489–99 doi:10.1210/jcem.87.2.8182 pmid:11836274
CrossRef PubMed
69.↵
2. Ferracci F,
3. Carnevale A
. The neurological disorder associated with thyroid autoimmunity. J Neurol 2006;253:975–84 doi:10.1007/s00415-006-0170-7 pmid:16786216
CrossRef PubMed
70.↵
2. Song YM,
3. Seo DW,
4. Chang GY
. MR findings in Hashimoto encephalopathy. AJNR Am J Neuroradiol 2004;25:807–08 pmid:15140725
Abstract/FREE Full Text
71.↵
2. Fujiki F,
3. Tsuboi Y,
4. Hashimoto K, et al
. Non-herpetic limbic encephalitis associated with relapsing polychondritis. J Neurol Neurosurg Psychiatry 2004;75:1646–47 doi:10.1136/jnnp.2003.035170 pmid:15489409
FREE Full Text
72.↵
2. Kumar N,
3. Leep Hunderfund AN,
4. Kutzbach BR, et al
. A limbic encephalitis MR imaging in a patient with Behcet disease and relapsing polychondritis. AJNR Am J Neuroradiol 2009;30:E96 doi:10.3174/ajnr.A1631 pmid:19386730
FREE Full Text
73.↵
2. Foidart JM,
3. Abe S,
4. Martin GR, et al
. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med 1978;299:1203–07 doi:10.1056/NEJM197811302992202 pmid:714080
CrossRef PubMed

View Abstract

In this issue

Download PDF

Email Article

Citation Tools

Purchase

Cited By...

More in this TOC Section

Show more ADULT BRAIN

[1] 1.↵

Brierley JB,
Corsellis JA,
Hierons R, et al
. Subacute encephalitis of later adult life mainly affecting the limbic areas. Brain 1960;83:357–68 doi:10.1093/brain/83.3.357
FREE Full Text

[3] Brierley JB,

[4] Corsellis JA,

[5] Hierons R, et al

[6] 2.↵

Vernino S,
Geschwind M,
Boeve B
. Autoimmune encephalopathies. Neurologist 2007;13:140–47 doi:10.1097/01.nrl.0000259483.70041.55 pmid:17495758
CrossRef PubMed

[8] Vernino S,

[9] Geschwind M,

[10] Boeve B

[11] 3.↵

Tüzun E,
Dalmau J
. Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist 2007;13:261–71 doi:10.1097/NRL.0b013e31813e34a5 pmid:17848866
CrossRef PubMed

[13] Tüzun E,

[14] Dalmau J

[15] 4.↵

Gultekin SH,
Rosenfeld MR,
Voltz R, et al
. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000;123(pt 7):1481–94 doi:10.1093/brain/123.7.1481 pmid:10869059
Abstract/FREE Full Text

[17] Gultekin SH,

[18] Rosenfeld MR,

[19] Voltz R, et al

[20] 5.↵

Vieira Santos A,
Matias S,
Saraiva P, et al
. Differential diagnosis of mesiotemporal lesions: case report of neurosyphilis. Neuroradiology 2005;47:664–67 doi:10.1007/s00234-005-1414-4 pmid:16021441
CrossRef PubMed

[22] Vieira Santos A,

[23] Matias S,

[24] Saraiva P, et al

[25] 6.↵

Kararizou E,
Markou I,
Zalonis I, et al
. Paraneoplastic limbic encephalitis presenting as acute viral encephalitis. J Neurooncol 2005;75:229–32 doi:10.1007/s11060-005-3671-9 pmid:16283448
CrossRef PubMed

[27] Kararizou E,

[28] Markou I,

[29] Zalonis I, et al

[30] 7.↵

Tyler KL
. Emerging viral infections of the central nervous system: part 1. Arch Neurol 2009;66:939–48 doi:10.1001/archneurol.2009.153 pmid:19667214
CrossRef PubMed

[32] Tyler KL

[33] 8.↵

Nagata R,
Ikeda K,
Nakamura Y, et al
. A case of gliomatosis cerebri mimicking limbic encephalitis: malignant transformation to glioblastoma. Int Med 2010;49:1307–10 doi:10.2169/internalmedicine.49.3278 pmid:20606365
CrossRef PubMed

[35] Nagata R,

[36] Ikeda K,

[37] Nakamura Y, et al

[38] 9.↵

Förster A,
Griebe M,
Gass A, et al
. Diffusion-weighted imaging for the differential diagnosis of disorders affecting the hippocampus. Cerebrovasc Dis 2012;33:104–15 doi:10.1159/000332036 pmid:22179485
CrossRef PubMed

[40] Förster A,

[41] Griebe M,

[42] Gass A, et al

[43] 10.↵

Armangue T,
Leypoldt F,
Dalmau J
. Autoimmune encephalitis as differential diagnosis of infectious encephalitis. Curr Opin Neurol 2014;27:361–68 doi:10.1097/WCO.0000000000000087 pmid:24792345
CrossRef PubMed

[45] Armangue T,

[46] Leypoldt F,

[47] Dalmau J

[48] 11.↵

Kotsenas AL,
Watson RE,
Pittock SJ, et al
. MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis. AJNR Am J Neuroradiol 2014;35:84–89 doi:10.3174/ajnr.A3633 pmid:23868165
Abstract/FREE Full Text

[50] Kotsenas AL,

[51] Watson RE,

[52] Pittock SJ, et al

[53] 12.↵

Oyanguren B,
Sánchez V,
González FJ, et al
. Limbic encephalitis: a clinical-radiological comparison between herpetic and autoimmune etiologies. Eur J Neurol 2013;20:1566–70 doi:10.1111/ene.12249 pmid:23941332
CrossRef PubMed

[55] Oyanguren B,

[56] Sánchez V,

[57] González FJ, et al

[58] 13.↵

Dalmau J,
Bataller L
. Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders. Hematol Oncol Clin North Am 2006;20:1319–35 doi:10.1016/j.hoc.2006.09.011 pmid:17113466
CrossRef PubMed

[60] Dalmau J,

[61] Bataller L

[62] 14.↵

Demaerel P,
Van Dessel W,
Van Paesschen W, et al
. Autoimmune-mediated encephalitis. Neuroradiology 2011;53:837–51 doi:10.1007/s00234-010-0832-0 pmid:21271243
CrossRef PubMed

[64] Demaerel P,

[65] Van Dessel W,

[66] Van Paesschen W, et al

[67] 15.↵

Darnell RB,
Posner JB
. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003;349:1543–54 doi:10.1056/NEJMra023009 pmid:14561798
CrossRef PubMed

[69] Darnell RB,

[70] Posner JB

[71] 16.↵

Dalmau J,
Rosenfeld MR
. Autoimmune encephalitis update. Neuro Oncol 2014;16:771–78 doi:10.1093/neuonc/nou030 pmid:24637228
Abstract/FREE Full Text

[73] Dalmau J,

[74] Rosenfeld MR

[75] 17.↵

Graus F,
Ariño H,
Dalmau J
. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood 2014;123:3230–38 doi:10.1182/blood-2014-03-537506 pmid:24705493
Abstract/FREE Full Text

[77] Graus F,

[78] Ariño H,

[79] Dalmau J

[80] 18.↵

Graus F,
Keime-Guibert F,
Reñe R, et al
. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124(pt 6):1138–48 doi:10.1093/brain/124.6.1138 pmid:11353730
Abstract/FREE Full Text

[82] Graus F,

[83] Keime-Guibert F,

[84] Reñe R, et al

[85] 19.↵

Shavit YB,
Graus F,
Probst A, et al
. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol 1999;45:255–58 doi:10.1002/1531-8249(199902)45:23.0.CO;2-N pmid:9989630
CrossRef PubMed

[87] Shavit YB,

[88] Graus F,

[89] Probst A, et al

[90] 20.↵

Keime-Guibert F,
Graus F,
Fleury A, et al
. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000;68:479–82 doi:10.1136/jnnp.68.4.479 pmid:10727484
Abstract/FREE Full Text

[92] Keime-Guibert F,

[93] Graus F,

[94] Fleury A, et al

[95] 21.↵

Rosenfeld MR,
Eichen JG,
Wade DF, et al
. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001;50:339–48 doi:10.1002/ana.1288 pmid:11558790
CrossRef PubMed

[97] Rosenfeld MR,

[98] Eichen JG,

[99] Wade DF, et al

[100] 22.↵

Dalmau J,
Graus F,
Villarejo A, et al
. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004;127(pt 8):1831–44 doi:10.1093/brain/awh203 pmid:15215214
Abstract/FREE Full Text

[102] Dalmau J,

[103] Graus F,

[104] Villarejo A, et al

[105] 23.↵

Dalmau J,
Gultekin SH,
Voltz R, et al
. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999;122(pt 1):27–39 doi:10.1093/brain/122.1.27 pmid:10050892
Abstract/FREE Full Text

[107] Dalmau J,

[108] Gultekin SH,

[109] Voltz R, et al

[110] 24.↵

Honnorat J,
Cartalat-Carel S,
Ricard D, et al
. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009;80:412–16 doi:10.1136/jnnp.2007.138016 pmid:18931014
Abstract/FREE Full Text

[112] Honnorat J,

[113] Cartalat-Carel S,

[114] Ricard D, et al

[115] 25.↵

Vernino S,
Tuite P,
Adler CH, et al
. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002;51:625–30 doi:10.1002/ana.10178 pmid:12112110
CrossRef PubMed

[117] Vernino S,

[118] Tuite P,

[119] Adler CH, et al

[120] 26.↵

Gable MS,
Sheriff H,
Dalmau J, et al
. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012;54:899–904 doi:10.1093/cid/cir1038 pmid:22281844
Abstract/FREE Full Text

[122] Gable MS,

[123] Sheriff H,

[124] Dalmau J, et al

[125] 27.↵

Titulaer MJ,
McCracken L,
Gabilondo I, et al
. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157–65 doi:10.1016/S1474-4422(12)70310-1 pmid:23290630
CrossRef PubMed

[127] Titulaer MJ,

[128] McCracken L,

[129] Gabilondo I, et al

[130] 28.↵

Irani SR,
Bera K,
Waters P, et al
. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133(pt 6):1655–67 doi:10.1093/brain/awq113 pmid:20511282
Abstract/FREE Full Text

[132] Irani SR,

[133] Bera K,

[134] Waters P, et al

[135] 29.↵

Kayser MS,
Titulaer MJ,
Gresa-Arribas N, et al
. Frequency and characteristics of isolated psychiatric episodes in anti–N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 2013;70:1133–39 doi:10.1001/jamaneurol.2013.3216 pmid:23877059
CrossRef PubMed

[137] Kayser MS,

[138] Titulaer MJ,

[139] Gresa-Arribas N, et al

[140] 30.↵

Dalmau J,
Gleichman AJ,
Hughes EG, et al
. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–98 doi:10.1016/S1474-4422(08)70224-2 pmid:18851928
CrossRef PubMed

[142] Dalmau J,

[143] Gleichman AJ,

[144] Hughes EG, et al

[145] 31.↵

Dalmau J,
Tüzün E,
Wu HY, et al
. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36 doi:10.1002/ana.21050 pmid:17262855
CrossRef PubMed

[147] Dalmau J,

[148] Tüzün E,

[149] Wu HY, et al

[150] 32.↵

Titulaer MJ,
McCracken L,
Gabilondo I, et al
. Late-onset anti-NMDA receptor encephalitis. Neurology 2013;81:1058–63 doi:10.1212/WNL.0b013e3182a4a49c pmid:23946310
Abstract/FREE Full Text

[152] Titulaer MJ,

[153] McCracken L,

[154] Gabilondo I, et al

[155] 33.↵

Johnson N,
Henry C,
Fessler AJ, et al
. Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology 2010;75:1480–82 doi:10.1212/WNL.0b013e3181f8831a pmid:20826712
FREE Full Text

[157] Johnson N,

[158] Henry C,

[159] Fessler AJ, et al

[160] 34.↵

Lancaster E,
Lai M,
Peng X, et al
. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010;9:67–76 doi:10.1016/S1474-4422(09)70324-2 pmid:19962348
CrossRef PubMed

[162] Lancaster E,

[163] Lai M,

[164] Peng X, et al

[165] 35.↵

Höftberger R,
Titulaer MJ,
Sabater L, et al
. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013;81:1500–06 doi:10.1212/WNL.0b013e3182a9585f pmid:24068784
Abstract/FREE Full Text

[167] Höftberger R,

[168] Titulaer MJ,

[169] Sabater L, et al

[170] 36.↵

Boronat A,
Sabater L,
Saiz A, et al
. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011;76:795–800 doi:10.1212/WNL.0b013e31820e7b8d pmid:21357831
Abstract/FREE Full Text

[172] Boronat A,

[173] Sabater L,

[174] Saiz A, et al

[175] 37.↵

Petit-Pedrol M,
Armangue T,
Peng X, et al
. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014;13:276–86 doi:10.1016/S1474-4422(13)70299-0 pmid:24462240
CrossRef PubMed

[177] Petit-Pedrol M,

[178] Armangue T,

[179] Peng X, et al

[180] 38.↵

Graus F,
Boronat A,
Xifró X, et al
. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010;74:857–59 doi:10.1212/WNL.0b013e3181d3e404 pmid:20211911
FREE Full Text

[182] Graus F,

[183] Boronat A,

[184] Xifró X, et al

[185] 39.↵

Carr I
. The Ophelia syndrome: memory loss in Hodgkin's disease. Lancet 1982;1:844–45 pmid:6122069
CrossRef PubMed

[187] Carr I

[188] 40.↵

Mat A,
Adler H,
Merwick A, et al
. Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF. Neurology 2013;80:1349–50 doi:10.1212/WNL.0b013e31828ab325 pmid:23486886
Abstract/FREE Full Text

[190] Mat A,

[191] Adler H,

[192] Merwick A, et al

[193] 41.↵

Malter MP,
Helmstaedter C,
Urbach H, et al
. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010;67:470–78 doi:10.1002/ana.21917 pmid:20437582
CrossRef PubMed

[195] Malter MP,

[196] Helmstaedter C,

[197] Urbach H, et al

[198] 42.↵

Grau-Rivera O,
Sánchez-Valle R,
Saiz A, et al
. Determination of neuronal antibodies in suspected and definite Creutzfeldt-Jakob disease. JAMA Neurol 2014;71:74–78 doi:10.1001/jamaneurol.2013.4857 pmid:24248099
CrossRef PubMed

[200] Grau-Rivera O,

[201] Sánchez-Valle R,

[202] Saiz A, et al

[203] 43.↵

Paterson RW,
Zandi MS,
Armstrong R, et al
. Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry 2014;85:625–30 doi:10.1136/jnnp-2013-305218 pmid:23757422
Abstract/FREE Full Text

[205] Paterson RW,

[206] Zandi MS,

[207] Armstrong R, et al

[208] 44.↵

Irani SR,
Michell AW,
Lang B, et al
. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69:892–900 doi:10.1002/ana.22307 pmid:21416487
CrossRef PubMed

[210] Irani SR,

[211] Michell AW,

[212] Lang B, et al

[213] 45.↵

Hiraga A,
Kuwabara S,
Hayakawa S, et al
. Voltage-gated potassium channel antibody-associated encephalitis with basal ganglia lesions. Neurology 2006;66:1780–81 doi:10.1212/01.wnl.0000218157.53333.79 pmid:16769968
FREE Full Text

[215] Hiraga A,

[216] Kuwabara S,

[217] Hayakawa S, et al

[218] 46.↵

Majoie HJ,
de Baets M,
Renier W, et al
. Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res 2006;71:135–41 doi:10.1016/j.eplepsyres.2006.06.003 pmid:16870397
CrossRef PubMed

[220] Majoie HJ,

[221] de Baets M,

[222] Renier W, et al

[223] 47.↵

Vincent A,
Buckley C,
Schott JM, et al
. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127(pt 3):701–12 doi:10.1093/brain/awh077 pmid:14960497
Abstract/FREE Full Text

[225] Vincent A,

[226] Buckley C,

[227] Schott JM, et al

[228] 48.↵

Lancaster E,
Huijbers MG,
Bar V, et al
. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011;69:303–11 doi:10.1002/ana.22297 pmid:21387375
CrossRef PubMed

[230] Lancaster E,

[231] Huijbers MG,

[232] Bar V, et al

[233] 49.↵

Blanc F,
Ben Abdelghani K,
Schramm F, et al
. Whipple limbic encephalitis. Arch Neurol 2011;68:1471–73 doi:10.1001/archneurol.2011.532 pmid:22084133
CrossRef PubMed

[235] Blanc F,

[236] Ben Abdelghani K,

[237] Schramm F, et al

[238] 50.↵

Badruddin A,
Menon RS,
Reder AT
. 4-Aminopyridine toxicity mimics autoimmune-mediated limbic encephalitis. Neurology 2009;72:1100–01 doi:10.1212/01.wnl.0000345063.17185.13 pmid:19307545
FREE Full Text

[240] Badruddin A,

[241] Menon RS,

[242] Reder AT

[243] 51.↵

Boeve BF,
Bell DG,
Noseworthy JH
. Bilateral temporal lobe MRI changes in uncomplicated hypoglycemic coma. Can J Neurol Sci 1995;22:56–8 pmid:7750077
PubMed

[245] Boeve BF,

[246] Bell DG,

[247] Noseworthy JH

[248] 52.↵

Baringer JR
. Herpes simplex infections of the nervous system. Neurol Clin 2008;26:657–74, viii doi:10.1016/j.ncl.2008.03.005 pmid:18657720
CrossRef PubMed

[250] Baringer JR

[251] 53.↵

Armangue T,
Leypoldt F,
Málaga I, et al
. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014;75:317–23 doi:10.1002/ana.24083 pmid:24318406
CrossRef PubMed

[253] Armangue T,

[254] Leypoldt F,

[255] Málaga I, et al

[256] 54.↵

Schäbitz WR,
Rogalewski A,
Hagemeister C, et al
. VZV brainstem encephalitis triggers NMDA receptor immunoreaction. Neurology 2014;83:2309–11 doi:10.1212/WNL.0000000000001072 pmid:25378669
Abstract/FREE Full Text

[258] Schäbitz WR,

[259] Rogalewski A,

[260] Hagemeister C, et al

[261] 55.↵

Höftberger R,
Armangue T,
Leypoldt F, et al
. Clinical neuropathology practice guide 4–2013: post-herpes simplex encephalitis: N-methyl-Daspartate receptor antibodies are part of the problem. Clin Neuropathol 2013;32:251–54 doi:10.5414/NP300666 pmid:23806220
CrossRef PubMed

[263] Höftberger R,

[264] Armangue T,

[265] Leypoldt F, et al

[266] 56.↵

Karsan N,
Barker R,
O'Dwyer JP
. Clinical reasoning: the “great imitator.” Neurology 2014;83:e188–96 doi:10.1212/WNL.0000000000001033 pmid:25422404
Abstract/FREE Full Text

[268] Karsan N,

[269] Barker R,

[270] O'Dwyer JP

[271] 57.↵

Vates GE,
Chang S,
Lamborn KR, et al
. Gliomatosis cerebri: a review of 22 cases. Neurosurgery 2003;53:261–71, discussion 271 doi:10.1227/01.NEU.0000073527.20655.E6 pmid:12925240
CrossRef PubMed

[273] Vates GE,

[274] Chang S,

[275] Lamborn KR, et al

[276] 58.↵

Maia AC Jr.,
Malheiros SM,
da Rocha AJ, et al
. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion-weighted magnetic resonance imaging. J Neurosurg 2004;101:970–76 doi:10.3171/jns.2004.101.6.0970 pmid:15597757
CrossRef PubMed

[278] Maia AC Jr.,

[279] Malheiros SM,

[280] da Rocha AJ, et al

[281] 59.↵

Sedlaczek O,
Hirsch JG,
Grips E, et al
. Detection of delayed focal MR changes in the lateral hippocampus in transient global amnesia. Neurology 2004;62:2165–70 doi:10.1212/01.WNL.0000130504.88404.C9 pmid:15210876
Abstract/FREE Full Text

[283] Sedlaczek O,

[284] Hirsch JG,

[285] Grips E, et al

[286] 60.↵

Cendes F
. Febrile seizures and mesial temporal sclerosis. Curr Opin Neurol 2004;17:161–64 doi:10.1097/00019052-200404000-00013 pmid:15021243
CrossRef PubMed

[288] Cendes F

[289] 61.↵

Kim JA,
Chung JI,
Yoon PH, et al
. Transient MR signal changes in patients with generalized tonicoclonic seizure or status epilepticus: periictal diffusion-weighted imaging. AJNR Am J Neuroradiol 2001;22:1149–60 pmid:11415912
Abstract/FREE Full Text

[291] Kim JA,

[292] Chung JI,

[293] Yoon PH, et al

[294] 62.↵

Cox JE,
Mathews VP,
Santos CC, et al
. Seizure-induced transient hippocampal abnormalities on MR: correlation with positron emission tomography and electroencephalography. AJNR Am J Neuroradiol 1995;16:1736–38 pmid:7502985
Abstract

[296] Cox JE,

[297] Mathews VP,

[298] Santos CC, et al

[299] 63.↵

Hatanpaa KJ,
Blass DM,
Pletnikova O, et al
. Most cases of dementia with hippocampal sclerosis may represent frontotemporal dementia. Neurology 2004;63:538–42 doi:10.1212/01.WNL.0000129543.46734.C0 pmid:15304590
Abstract/FREE Full Text

[301] Hatanpaa KJ,

[302] Blass DM,

[303] Pletnikova O, et al

[304] 64.↵

Caraballo RH,
Reyes G,
Avaria MF, et al
. Febrile infection-related epilepsy syndrome: a study of 12 patients. Seizure 2013;22:553–59 doi:10.1016/j.seizure.2013.04.005 pmid:23643626
CrossRef PubMed

[306] Caraballo RH,

[307] Reyes G,

[308] Avaria MF, et al

[309] 65.↵

van Baalen A,
Häusler M,
Boor R, et al
. Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood. Epilepsia 2010;51:1323–28 doi:10.1111/j.1528-1167.2010.02535.x pmid:20345937
CrossRef PubMed

[311] van Baalen A,

[312] Häusler M,

[313] Boor R, et al

[314] 66.↵

Venkatesan A,
Benavides DR
. Autoimmune encephalitis and its relation to infection. Curr Neurol Neurosci Rep 2015;15:3 doi:10.1007/s11910-015-0529 pmid:25637289
CrossRef PubMed

[316] Venkatesan A,

[317] Benavides DR

[318] 67.↵

Castillo P,
Woodruff B,
Caselli R, et al
. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006;63:197–202 doi:10.1001/archneur.63.2.197 pmid:16476807
CrossRef PubMed

[320] Castillo P,

[321] Woodruff B,

[322] Caselli R, et al

[323] 68.↵

Hollowell JG,
Staehling NW,
Flanders WD, et al
. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489–99 doi:10.1210/jcem.87.2.8182 pmid:11836274
CrossRef PubMed

[325] Hollowell JG,

[326] Staehling NW,

[327] Flanders WD, et al

[328] 69.↵

Ferracci F,
Carnevale A
. The neurological disorder associated with thyroid autoimmunity. J Neurol 2006;253:975–84 doi:10.1007/s00415-006-0170-7 pmid:16786216
CrossRef PubMed

[330] Ferracci F,

[331] Carnevale A

[332] 70.↵

Song YM,
Seo DW,
Chang GY
. MR findings in Hashimoto encephalopathy. AJNR Am J Neuroradiol 2004;25:807–08 pmid:15140725
Abstract/FREE Full Text

[334] Song YM,

[335] Seo DW,

[336] Chang GY

[337] 71.↵

Fujiki F,
Tsuboi Y,
Hashimoto K, et al
. Non-herpetic limbic encephalitis associated with relapsing polychondritis. J Neurol Neurosurg Psychiatry 2004;75:1646–47 doi:10.1136/jnnp.2003.035170 pmid:15489409
FREE Full Text

[339] Fujiki F,

[340] Tsuboi Y,

[341] Hashimoto K, et al

[342] 72.↵

Kumar N,
Leep Hunderfund AN,
Kutzbach BR, et al
. A limbic encephalitis MR imaging in a patient with Behcet disease and relapsing polychondritis. AJNR Am J Neuroradiol 2009;30:E96 doi:10.3174/ajnr.A1631 pmid:19386730
FREE Full Text

[344] Kumar N,

[345] Leep Hunderfund AN,

[346] Kutzbach BR, et al

[347] 73.↵

Foidart JM,
Abe S,
Martin GR, et al
. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med 1978;299:1203–07 doi:10.1056/NEJM197811302992202 pmid:714080
CrossRef PubMed

[349] Foidart JM,

[350] Abe S,

[351] Martin GR, et al

Main menu

User menu

Search